Improving venous symptoms in C0s-C1s patients after multicomponent diosmin-based preparation: Initial experience.

IF 1.6 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

Phlebology Pub Date : 2023-06-01 DOI:10.1177/02683555231169088

Michele Greco, Daniele Bissacco

引用次数: 0

Abstract

The use of drug therapies in patients with chronic venous disease (CVD) remains a topic of debate regarding safety, compliance, and effectiveness. Although the beneficial effects of molecules like diosmin have been established in patients with chronic venous insufficiency (CVI) of C3-C6 classes, the evidence for its use in C0-C1 patients is not well documented. This report aims to describe and analyze the positive impact of a new diosmin-based drug therapy on a population of C0-C1 patients in terms of relief of venous symptoms.

查看原文本刊更多论文

多组分地奥辛制剂改善c0 - c1s患者静脉症状:初步经验。

在慢性静脉疾病(CVD)患者中使用药物治疗仍然是一个关于安全性、依从性和有效性的争论话题。虽然像地奥司明这样的分子在C3-C6级慢性静脉功能不全(CVI)患者中的有益作用已经确立，但其在C0-C1级患者中的应用证据并没有很好的文献记载。本报告旨在描述和分析一种新的基于薯蓣皂苷的药物治疗在缓解静脉症状方面对C0-C1患者群体的积极影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phlebology 医学-外周血管病

CiteScore

3.30

自引率

11.80%

发文量

审稿时长

6-12 weeks

期刊介绍： The leading scientific journal devoted entirely to venous disease, Phlebology is the official journal of several international societies devoted to the subject. It publishes the results of high quality studies and reviews on any factor that may influence the outcome of patients with venous disease. This journal provides authoritative information about all aspects of diseases of the veins including up to the minute reviews, original articles, and short reports on the latest treatment procedures and patient outcomes to help medical practitioners, allied health professionals and scientists stay up-to-date on developments. Print ISSN: 0268-3555